New Glioblastoma Vaccine Shows Promising Results in Phase Ib Clinical Trial
Glioblastoma is the most aggressive type of primary brain cancer, one with a prognosis of 11-15 months with standard treatment. Results from a phase 1b clinical trial of a new experimental glioblastoma vaccine developed by Jefferson and Imvax, show the treatment was tolerated well by patients, slowed tumor recurrence, and prolonged patient survival.
Researchers treated 33 patients with newly diagnosed glioblastoma multiforme with the novel cancer vaccine (IGV-001) in a prospective phase 1b clinical study and compared outcomes to a historical comparator group of 35 patients treated with standard of care at the same institution. The results showed patients treated with the vaccine had improved progression-free survival and overall survival compared to the control group treated with standard of care alone.
“The response we see in some patients is very encouraging,” says David Andrews, MD, Professor of Neurosurgery at the Vickie & Jack Farber Institute for Neuroscience — Jefferson Health and co-founder, Chief Medical Officer and interim Chief Executive Officer of Imvax. “We look forward to initiating a phase II trial later this year to confirm these phase 1b results.”
The New England Master Class - Anterior Skull Base Surgery
May 20-21, 2019; Boston
6th Annual Meeting on Neurosurgery and Neurologica
May 22-23, 2019; London
INS 14th World Congress
May 25-30, 2019; Sydney
12th Annual Cervical Spine Research Society Hands-on Cadaver Course
May 30-June 1, 2019; St. Louis
Brain Tumor Biotech Summit
June 7, 2019; New York
Be the first to reply using the above form.